When activated by its target, the newly characterized molecule rips the genome apart, a lethal move that researchers can ...

Detailed price information for Editas Medicine (EDIT-Q) from The Globe and Mail including charting and trades.

Intellia Therapeutics (NTLA) is a clinical-stage biotech firm working on CRISPR-based treatments that try to edit genes ...

Individuals that share the same deletion of a portion of chromosome 16 are at risk of developing neurodevelopmental disorders ...

It is natural to wonder whether the world is on the cusp of a nightmarish age of AI -enabled bioterrorism—and, if so, what ...

The gene-editing drug is designed to treat patients with elevated low-density lipoprotein cholesterol or serum triglycerides.

Stuart Orkin and Swee Lay Thein shared a Breakthrough Prize in Life Sciences for their research on genetic causes of sickle ...

CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first ...

A Hiroshima-University-led research team has discovered a key gene responsible for the initiation of gemma development, ...

Growth is driven by supportive innovation pathways, increasing chronic disease prevalence, aging populations, and sustained ...